Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06251076
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-02-01
Brief Title:
Plan Development for Giving Teclistamab in the Outpatient Setting
Sponsor:
University Health Network Toronto
Organization:
University Health Network Toronto
Study Overview
Official Title:
Outpatient-based Teclistamab Step-up Dosing in Patients With RelapsedRefractory Multiple Myeloma Process Development in Academic and Community Centres and Evaluating Impact on Caregiver Burden
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsedrefractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CAPCR 23-5935 | OTHER | None | None |
| 64007957MMY4009 | OTHER | Janssen Inc | None |